Study of Tremelimumab in Patients With Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Urothelial Bladder Cancer|Triple-negative Breast Cancer|Pancreatic Ductal Adenocarcinoma
Interventions: BIOLOGICAL: Tremelimumab monotherapy|BIOLOGICAL: MEDI4736 monotherapy|BIOLOGICAL: MEDI4736 + tremelimumab combination therapy
Sponsor: AstraZeneca